OcuMedic’s TechnologyOcuMedic’s technology was developed by Dr. Mark Byrne, Distinguished Professor of Chemical and Biomedical Engineering & Founding Head of the Biomedical Engineering Department at Rowen University and his research team. Dr. Byrne serves as Co-founder of OcuMedic and Chief Technical Officer. The technology rests on 9 issued patents, efficacy has been proven in an animal model. The intellectual property teaches a novel therapeutic contact lens with memory capable of controlled release of first line ophthalmic agents, both inflammatory and antibiotic. The technology has been developed for the most common and widely used contact lens material silicon hydrogel, (SiHy). The technology is also a platform technology and has been tested for a wide range of other drugs as well as molecules to enhance lens comfort and treat dry eye.
Controlled release from contact lenses has been the subject of discussions and investigation for fifty, (50) years. Previous methods suffer from either poor control of the release profile or inadequate drug loading with the overwhelming majority of researchers demonstrating both problems. Thus there are no products on the market today. With the OcuMedic’s method memory for the drug is produced during polymer synthesis where monomers are complexed non-covalently to the drug and crosslinked into a hydrogel matrix. Upon removal of the drug, macromolecular memory sites remain within the hydrogel with affinity for the drug. The drug’s heightened interaction with these memory pockets enhances its loading and SLOWS its transport within the hydrogel despite comparable free volume of drug transport. It has been shown that the extension of release has a strong dependence on mimicking biological recognition in the design exploiting the chemical diversity and amounts of monomers in relation to the drug. Thus OcuMedic’s can literally…. DIAL IN THE RELEASE OF DRUG FROM THE LENS OVER TIME delivering a therapeutic concentration of drug payload for the duration of wear.